<DOC>
	<DOCNO>NCT00004814</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare tolerance therapeutic impact copolymer 1 , mixture synthetic polypeptide , placebo patient relapsing-remitting multiple sclerosis .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study Copolymer 1 Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution . One group receive copolymer 1 , mixture synthetic polypeptide compose 4 amino acid , subcutaneously day 2 year . The group receive injection placebo daily 2 year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Clinically laboratorysupported definite multiple sclerosis Neurologically stable least 30 day prior entry Expanded Disability Status Scale score great 5 At least 2 documented relapse within 2 year prior entry Onset first relapse least 1 year prior randomization Prior/Concurrent Therapy Biologic therapy : No prior copolymer 1 Immunosuppressive therapy : No prior cytotoxic immunosuppressive , i.e . : Azathioprine Cyclophosphamide Cyclosporine At least 30 day since corticosteroid Radiotherapy : No prior lymphoid irradiation Patient Characteristics Not HIV HTLVI seropositive No insulindependent diabetes mellitus No Lyme disease No requirement aspirin chronic nonsteroidal antiinflammatory drug No pregnant nursing woman Adequate contraception require fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 1997</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>